抗凝固疗法对患有表症的患者医疗保健利用的影响
Boston Andersen1, Alec Kadrie1, Meghana Chanamolu2
1University of Tennessee Health Science Center, School of Medicine Memphis Tennessee USA.
Laryngoscope investigative otolaryngology
|November 20, 2025
概括
服用抗凝血剂而经历鼻血 (表) 的患者在医疗保健使用率较高. 这包括更多的医院护理,急诊室访问和胸部成像,而不是抗凝剂.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 鼻出血 (epistaxis) 是一个常见的疾病.
- 抗凝固药物治疗可以增加出血风险.
- 抗凝剂对与表皮质相关的医疗保健利用的影响尚未完全理解.
研究的目的:
- 为了比较成人表症患者的医疗保健利用率,使用和不使用抗凝剂.
- 为了确定特定的医疗保健服务与抗凝剂在表患者.
主要方法:
- 对TrinetX数据集 (2014-2024) 的回顾性分析.
- 两个匹配的队列的比较:带有抗凝剂和没有抗凝剂的表皮术患者.
- 结果包括医院护理,急诊室 (ED) 服务,观察服务,胸部成像和出血控制程序.
主要成果:
- 抗凝血表皮术患者在随后的医院护理 (RR 5.99),ED服务 (RR 2.70),医院观察 (RR 3.00) 和胸部成像 (RR 3.92) 中的风险显著增加.
- 在抗凝固剂组 (p=0.019) 中,ED服务的显著增加.
- 没有抗凝药的患者更有可能需要前鼻出血控制 (p<0.001对于简单和复杂的方法).
结论:
- 抗凝固疗法与显著增加的医疗保健利用率有关,用于表管理.
- 仔细监测和量身定制的管理策略对于服用抗凝药的表症患者至关重要.
- 调查结果强调了需要主动照顾,以减轻这一群体的医疗负担.
更多相关视频
相关概念视频
Epistaxis
506
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
506
Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis IV: Nursing Management
188
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
188
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K


